Mar Tintore
Overview
Explore the profile of Mar Tintore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
214
Citations
7415
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vaccination in multiple sclerosis: Tackling challenges and paving the way for effective immunization
Carvajal R, Tur C, Borras-Bermejo B, Saylor D, Montalban X, Tintore M, et al.
Mult Scler
. 2025 Mar;
:13524585251318513.
PMID: 40071952
Background: Vaccination in patients with multiple sclerosis (PwMS) presents unique challenges. Disease-modifying therapies (DMTs) can increase infectious risks, though these are largely preventable through immunizations. However, DMTs can also reduce...
2.
Marignier R, Villacieros-Alvarez J, Espejo C, Arrambide G, Fissolo N, Gutierrez L, et al.
J Neurol Neurosurg Psychiatry
. 2025 Feb;
PMID: 39939136
Background: Serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) have emerged as important biomarkers in multiple sclerosis (MS) and aquaporin-4 seropositive neuromyelitis optica spectrum disorder (AQP4-NMOSD)....
3.
Marrodan M, Sao Aviles A, Rio J, Cobo-Calvo A, Fernandez V, Pappolla A, et al.
Mult Scler
. 2025 Feb;
:13524585251316471.
PMID: 39925147
Background: Predicting treatment response and disease progression in multiple sclerosis (MS) is challenging. Treatment Response Scoring Systems (TRSS) are potentially useful, but their utility in patients receiving high-efficacy therapies and...
4.
Vilaseca A, Tintore M, Carbonell-Mirabent P, Rodriguez-Barranco M, Arevalo M, Arino H, et al.
Mult Scler
. 2025 Feb;
:13524585251314749.
PMID: 39907218
Background: It is essential to exclude alternative diagnoses to diagnose multiple sclerosis (MS). However, detailed descriptions of alternative diagnoses in patients with suspected MS presenting with clinically isolated syndrome (CIS)...
5.
Cobo-Calvo A, Carbonell-Mirabent P, Tur C, Otero-Romero S, Carvajal R, Arrambide G, et al.
Neurology
. 2025 Feb;
104(4):e210305.
PMID: 39903901
Background And Objectives: Emerging concepts in the early detection of multiple sclerosis (MS) progression reveal that disability accumulation can start early in the disease course. Aging in MS is increasingly...
6.
Comabella M, Pappolla A, Monreal E, Fissolo N, Sao-Aviles A, Arrambide G, et al.
Neurol Neuroimmunol Neuroinflamm
. 2025 Jan;
12(2):e200370.
PMID: 39879564
Background And Objectives: Invasive procedures may delay the diagnostic process in multiple sclerosis (MS). We investigated the added value of serum neurofilament light chain (sNfL), glial fibrillary acidic protein (sGFAP),...
7.
Carvajal R, Guananga-Alvarez D, Tur C, Esperalba J, Rodriguez-Barranco M, Rando-Segura A, et al.
Neurology
. 2025 Jan;
104(3):e210281.
PMID: 39819099
Background And Objectives: Hepatitis B vaccination (HBV) requires 6 months to complete and is recommended for patients with multiple sclerosis (PWMS), particularly those who are candidates for anti-CD20 therapy. However,...
8.
Muraro P, Mariottini A, Greco R, Burman J, Iacobaeus E, Inglese M, et al.
Nat Rev Neurol
. 2025 Jan;
21(3):140-158.
PMID: 39814869
Autologous haematopoietic stem cell transplantation (AHSCT) is a treatment option for relapsing forms of multiple sclerosis (MS) that are refractory to disease-modifying therapy (DMT). AHSCT after failure of high-efficacy DMT...
9.
Villacieros-Alvarez J, Espejo C, Arrambide G, Dinoto A, Mulero P, Rubio-Flores L, et al.
Neurol Neuroimmunol Neuroinflamm
. 2025 Jan;
12(2):e200362.
PMID: 39752619
Objectives: To characterize the serum cytokine profile in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) at onset and during follow-up and assess their utility for predicting relapses and disability. Methods: This...
10.
Androdias G, Lunemann J, Maillart E, Amato M, Audoin B, Bruijstens A, et al.
Brain
. 2024 Dec;
PMID: 39707906
The development of disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS) has been highly successful in recent decades. It is now widely accepted that early initiation of DMTs...